Pacira BioSciences, Inc. (PCRX)

Operating profit margin

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Operating income (ttm) US$ in thousands -68,733 -59,471 97,777 106,679 103,712 86,854 80,644 52,675 57,920 45,024 64,946 87,881 89,925 104,496 90,683 48,693 46,350 29,279 14,072 26,494
Revenue (ttm) US$ in thousands 700,966 694,957 690,310 681,754 674,978 665,689 669,229 669,173 666,823 654,062 614,318 580,497 541,533 510,887 500,649 440,564 427,221 421,097 408,298 435,397
Operating profit margin -9.81% -8.56% 14.16% 15.65% 15.37% 13.05% 12.05% 7.87% 8.69% 6.88% 10.57% 15.14% 16.61% 20.45% 18.11% 11.05% 10.85% 6.95% 3.45% 6.09%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $-68,733K ÷ $700,966K
= -9.81%

Pacira BioSciences, Inc.'s operating profit margin has shown fluctuations over the analyzed periods. The trend indicates an improvement from around 6% in early 2020 to a peak of over 20% in September 2021. However, there has been some volatility since then, with the margin decreasing to around 6% again by September 2022. Notably, in the most recent periods ending in 2024, the operating profit margin turned negative, falling to approximately -9.81% by December 2024. This suggests that the company's operating expenses may have outpaced its operating income during those periods. Further scrutiny and assessment of the company's cost structure and revenue generation are warranted to understand the reasons behind these fluctuations and the potential actions needed to improve profitability.